SCHEDULE: Venrock Healthcare Discloses 2.8% Stake in Enliven

Venrock Healthcare Capital Partners and affiliates report a 2.8% beneficial ownership stake in Enliven Therapeutics, Inc.

Summary

• Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, and Venrock Healthcare Capital Partners EG, L.P. collectively report beneficial ownership of 1,726,331 shares of Enliven Therapeutics, Inc. common stock.
• The reported holdings represent 2.8% of the total outstanding common stock of the issuer.
• The filing is an amendment (Amendment No. 4) to a previously filed Schedule 13G.
• The reporting persons certify that the shares are held for investment purposes and not to influence or change control of the company.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral regulatory disclosure reflecting existing investment positions without signaling a change in strategy or outlook.

Positives

• Continued investment interest from a specialized healthcare-focused venture capital firm.
• The reporting entities maintain a stable, non-activist position in the company.

Negatives

• The stake remains below the 5% threshold typically associated with significant institutional influence or major shareholder status.

Risks

• Market volatility affecting the valuation of the investment.
• General risks associated with biotechnology and pharmaceutical development inherent to the issuer's business.

Future Outlook

The reporting persons state that the securities were not acquired for the purpose of changing or influencing the control of the issuer.

Industry Context

StockSavvy.ai notes that Schedule 13G filings by venture capital firms in the biotech sector are standard practice for maintaining transparency regarding passive investment positions as companies progress through clinical development stages.

Comparison to Industry Standards

• The 2.8% ownership level is consistent with typical minority stake holdings by venture capital firms in mid-stage biotech companies.
• The filing follows standard SEC regulatory requirements for institutional investors.

Stakeholder Impact

• Minimal impact on shareholders as the filing confirms a passive investment stance.

Next Steps

• Continued monitoring of future 13G or 13D filings should the reporting group increase or decrease their position.

Key Dates

Keywords

Enliven Therapeutics, Venrock, Schedule 13G, Beneficial Ownership, Biotech Investment, Common Stock